Priel Eldar, Adatia Adil, Kjarsgaard Melanie, Nair Parameswaran
McMaster University Department of Medicine, Hamilton, Canada.
Firestone Institute for Respiratory Health, St Joseph's Healthcare Hamilton, 50 Charlton Avenue East, Hamilton, ON, L8N 4A6, Canada.
Allergy Asthma Clin Immunol. 2022 Jun 6;18(1):46. doi: 10.1186/s13223-022-00684-0.
Patients with asthma who have neutrophilic bronchitis may have an underlying cause leading to increased susceptibility to airway infections.
Retrospective review of patients with asthma who had a previous history of recurrent exacerbations that had been associated with airway or sinus infections referred to a tertiary asthma center between 2005 and 2020. Demographics, clinical features, and airway inflammation type determined by sputum cytometry were compared between CFTR carriers and non-carriers. Multiple linear regression was used to identify clinical predictors of CFTR carrier status. Response to nebulized hypertonic saline was assessed by comparing the number of infective exacerbations before and after its initiation.
75 patients underwent CFTR mutation testing. Of these, 13 (17%) were CFTR carriers. The most common mutation was [Formula: see text]F508. CFTR carriers were older (adjusted odds ratio 1.06 (CI 95% 1.01, 1.13)) and had more frequent flares requiring hospitalization (4.19 (1.34, 24.74)). Neutrophilic airway inflammation was the most common inflammatory subtype in CFTR carriers, though 8/13 also had eosinophilic bronchitis. Nebulized hypertonic saline was well tolerated by most and reduced the frequency of infective exacerbations.
The prevalence of CFTR heterozygosity in this cohort with recurrent neutrophilic bronchitis is higher than in the general population. Respiratory disease in CFTR carriers is associated with older age and may cause significant morbidity. Airway neutrophilia is the most common inflammatory subtype, but > 50% had eosinophilic bronchitis requiring treatment. Hypertonic saline appears to be well tolerated and effective in reducing the number of infective exacerbations.
患有嗜中性粒细胞性支气管炎的哮喘患者可能存在导致气道感染易感性增加的潜在病因。
对2005年至2020年间转诊至一家三级哮喘中心、有与气道或鼻窦感染相关的复发性加重病史的哮喘患者进行回顾性研究。比较了CFTR基因携带者和非携带者的人口统计学、临床特征以及通过痰液细胞计数确定的气道炎症类型。采用多元线性回归来确定CFTR基因携带者状态的临床预测因素。通过比较雾化高渗盐水开始前后感染性加重的次数来评估对雾化高渗盐水的反应。
75例患者接受了CFTR基因突变检测。其中,13例(17%)为CFTR基因携带者。最常见的突变是[公式:见正文]F508。CFTR基因携带者年龄较大(调整后的优势比为1.06(95%置信区间为1.01,1.13)),需要住院治疗的发作更频繁(4.19(1.34,24.74))。嗜中性粒细胞性气道炎症是CFTR基因携带者中最常见的炎症亚型,不过13例中有8例也患有嗜酸性粒细胞性支气管炎。大多数患者对雾化高渗盐水耐受性良好,且雾化高渗盐水降低了感染性加重的频率。
在这个患有复发性嗜中性粒细胞性支气管炎的队列中,CFTR基因杂合子的患病率高于一般人群。CFTR基因携带者的呼吸系统疾病与年龄较大有关,可能会导致显著的发病率。气道嗜中性粒细胞增多是最常见的炎症亚型,但超过50%的患者患有需要治疗的嗜酸性粒细胞性支气管炎。高渗盐水似乎耐受性良好,且在减少感染性加重次数方面有效。